1 November 2020 in Cell Reports
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is constantly evolving. Prior studies focused on high-case-density locations, such as the northern and western metropolitan areas of the United States. This study demonstrates continued SARS-CoV-2 evolution in a suburban southern region of the United States by high-density amplicon sequencing of symptomatic cases. 57% of strains carry the spike D614G variant, which is associated with higher genome copy numbers, and its prevalence expands with time. Four strains carry a deletion in a predicted stem loop of the 3′ UTR. The data are consistent with community spread within local populations and the larger continental United States. The data instill confidence in current testing sensitivity and validate “testing by sequencing” as an option to uncover cases, particularly nonstandard coronavirus disease 2019 (COVID-19) clinical presentations. This study contributes to the understanding of COVID-19 through an extensive set of genomes from a non-urban setting and informs vaccine design by defining D614G as a dominant and emergent SARS-CoV-2 isolate in the United States.
2 February 2022 in Virology
22 April 2026 in The Journal of Infectious Diseases
Background: HIV-1 RNA typically declines rapidly after initiation of antiretroviral therapy (ART), often reaching undetectable levels within a few weeks and remaining undetectable by standard assays. However, some patients receiving ART have persistent nonsuppressible viremia (NSV) that does not respond to treatment optimization or intensification. NSV can emerge at the time of ART initiation (primary NSV) or after being ART suppressed (secondary NSV). Here, we examine mechanisms producing primary NSV in 4 people undergoing ART. Methods: Blood samples were collected from 4 participants with advanced immunodeficiency who, despite being adherent to ART, required approximately a year or more to become virologically suppressed. Viral RNA and proviral DNA genomes were sequenced to examine HIV drug resistance, genome intactness, and genetic diversity. The ability of HIV Envs to facilitate efficient entry into cells expressing low levels of CD4, a proxy for macrophage tropism, was also assessed. Results: Before ART, blood contained HIV RNA genomes that were adapted to replication in CD4+ T cells and rapidly decayed after ART initiation. During ART, blood contained HIV genomes that were drug sensitive, genetically diverse, and macrophage tropic; moreover, they were not evolving and often had vpr defects. Conclusions: Our results suggest that in individuals with primary NSV, ART stopped virus replication, but large pools of long-lived HIV-infected macrophage continued to produce virus. This is mechanistically distinct from secondary NSV produced by CD4+ T-cell clones. Defects in vpr independently accumulated in macrophage-tropic lineages found in 3 participants, suggesting that vpr may affect survival or virus production from HIV-infected macrophage.